HAYWARD, Calif., March 14 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) announced today that Gary S. Titus, Kosan's Senior Vice President and Chief Financial Officer, will present at the Cowen and Company 28th Annual Health Care Conference in Boston at the Boston Marriott Copley Place on Wednesday, March 19, 2008 at 8:00 a.m. Eastern Time. A live webcast of the presentation can be accessed through http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=KOSN&item_id=17865 88.
Interested parties may also access a live webcast of the presentation by visiting the "Events Calendar" page under the "Investors/Press" tab on Kosan's website at http://www.kosan.com. A recorded replay of the presentation will be available for two weeks.
Kosan Biosciences is a biotechnology company advancing two new classes
of anticancer agents through clinical development -- Hsp90 (heat shock
protein 90) inhibitors and epothilones. Hsp90 inhibitors have a novel
mechanism of action targeting multiple pathways involved in cancer cell
growth and survival. Tanespimycin (KOS-953) is being tested in combination
with bortezomib (Velcade(R)) in patients with multiple myeloma in a
clinical program called TIME. Tanespimycin is also being studied in
HER2-positive metastatic breast cancer in combination with trastuzumab
(Herceptin(R)). Epothilones inhibit cell division with a mechanism of
action similar to taxanes, one of the most successful classes of anti-tumor
agents. KOS-1584 is in Phase 1 clinical trials in patients with solid
tumors. Kosan's motilin agonist compo
|SOURCE Kosan Biosciences Incorporated|
Copyright©2008 PR Newswire.
All rights reserved